

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: BRAVRBFLV

(Page 1 of 2)

| DOCTOR'S ORDERS   | Ht   | cm                 | Wt              | k         | BSA                 | m²                       |
|---|--|--------------------|-----------------|-----------|---------------------|--------------------------|
| REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form      |  |                    |                 |           |                     |                          |
| DATE: To be given: Cycle(s) #:  |  |                    |                 |           |                     |                          |
| Date of Previous Cycle:   |  |                    |                 |           |                     |                          |
| ☐ Delay treatment week(s)   |  |                    |                 |           |                     |                          |
| ☐ CBC & Diff, platelets, creatinine day of treate   | ment   |                    |                 |           |                     |                          |
| Cycles 1 to 6, for Day 1 and Day 15 (if ordered): Nor equal to 1.0 x 109/L, Platelets greater than o          |  |                    | as written      | if within | 48 hours <b>A</b> l | NC <u>greater than</u>   |
| Cycle 7 onwards: May proceed with doses as writ<br>Platelets greater than or equal to 75 x 10 <sup>9</sup> /L | tten if within 9                                       | 96 hours <b>AN</b> | C <u>greate</u> | r than or | equal to 1          | .0 x 10 <sup>9</sup> /L, |
| Dose modification for:   Other Toxicity   |  |                    |                 |           | _                   |                          |
| Proceed with treatment based on blood work f  | from   |                    |                 |           |                     |                          |
| TREATMENT:  |  |                    |                 |           |                     |                          |
| ribociclib 🗌 600 mg or 🔲 400 mg or 🔲 200 mg   | g (select one  | ) PO once d        | aily in the     | morning   | x 21 days           | on days 1 to 21,         |
| then 7 days off x cycle(s)  |  |                    |                 |           |                     |                          |
| <u>PLUS</u>   |  |                    |                 |           |                     |                          |
| Cycle 1:  |  |                    |                 |           |                     |                          |
| fulvestrant 500 mg IM once daily on Days 1 a<br>Administer as two 250 mg injections.                          | and 15.  |                    |                 |           |                     |                          |
| Cycle 2 onwards:  |  |                    |                 |           |                     |                          |
| fulvestrant 500 mg IM once daily on Day 1 or<br>Administer as two 250 mg injections.                          | f Cycle 2 the  | n repeat eve       | ery 28 day      | s. Mitte: | dose(               | s) Repeat x              |
| For women needing chemically induced meno   | pause and r  | nale patient       | s:              |           |                     |                          |
| PLUS  |  |                    |                 |           |                     |                          |
| goserelin long acting (ZOLADEX)   | ☐ <b>3.6 mg</b> subcutaneous every 4 weeks xtreatments |                    |                 |           |                     |                          |
| goserelin long acting (ZOLADEX LA)  | ☐ 10.8 mg subcutaneous every 12 weeks xtreatments      |                    |                 |           |                     |                          |
| OR  |  |                    |                 |           |                     |                          |
| leuprolide long acting (LUPRON DEPOT)   | 7.5 mg IM every 4 weeks xtreatments                    |                    |                 |           | nents               |                          |
|   | 22.5 mg IM every 12 weeks xtreatments                  |                    |                 |           |                     |                          |
|   |  |                    |                 |           |                     |                          |
| DOCTOR'S SIGNATURE:   |  |                    |                 |           | SIGNAT              | <br>URE:                 |
|   |  |                    |                 |           |                     |                          |
|   |  |                    |                 |           | UC:                 |                          |



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <a href="www.bccancer.bc.ca">www.bccancer.bc.ca</a> and according to acceptable standards of care

## PROTOCOL CODE: BRAVRBFLV

(Page 2 of 2)

| DOCTOR'S ORDERS   |            |
|---|------------|
| DATE:   |            |
| RETURN APPOINTMENT ORDERS   |            |
| Cycle 1:  |            |
| ☐ Book fulvestrant injections on Days 1 and 15.   |            |
| Return in <b>four</b> weeks for Doctor and Cycle 2.   |            |
| Cycles 2 to 6:  |            |
| ☐ Book fulvestrant injections on Day 1 of Cycle 2 then repeat every 28 days x   |            |
| injections.   |            |
| Return in 4 weeks for Doctor and Cycle  |            |
| Cycle 7 onwards:  |            |
| ☐ Book fulvestrant injections every 28 days x injections.   |            |
| Return in weeks for Doctor and Cycle  |            |
| Last Cycle. RTC in week(s).   |            |
| Cycle 1 (Day 15): CBC & diff, platelets, creatinine, albumin, ALT, alkaline phosphatase,  |            |
| total bilirubin, sodium, potassium, calcium, magnesium, phosphorus, ECG   |            |
| <b>Cycle 1 (Day 22):</b> CBC & diff, platelets if ANC on Day 15 is 0.5 to less than 1.0, or if platelets on Day 15 are 50 to less than 74   |            |
| Cycle 2 (Day 1): CBC & diff, platelets, creatinine, albumin, ALT, alkaline phosphatase,   |            |
| total bilirubin, sodium, potassium, calcium, magnesium, phosphorus, ECG   |            |
| ☐ Cycle 2 (Day 15): CBC & diff, platelets   |            |
| Cycle 2 (Day 22): CBC & diff, platelets if ANC on Day 15 is 0.5 to less than 1.0, or if platelets on Day 15 are 50 to less than 74  |            |
| <b>Cycles 3 to 6:</b> CBC & diff, platelets, creatinine, ALT, alkaline phosphatase, total bilirubin prior to each cycle.  |            |
| Cycles 7 onwards: CBC & diff, platelets, creatinine prior to  ach cycle   |            |
| every third cycle   |            |
| If clinically indicated:       ☐ Albumin       ☐ ALT       ☐ Alkaline phosphatase       ☐ Total Bilirubin         ☐ GGT       ☐ LDH       ☐ Sodium       ☐ Potassium       ☐ Calcium       ☐ Magnesium       ☐ Phosphorus         ☐ Serum cholesterol       ☐ Triglycerides       ☐ ECG       ☐ CA15-3       ☐ CEA       ☐ CA125         ☐ Other tests:       ☐ Consults: |            |
| ☐ See general orders sheet for further orders   |            |
| DOCTOR'S SIGNATURE:   | SIGNATURE: |
|   | UC:        |